Tumor necrosis factor α induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: Inhibition by simvastatin

Cardiovascular Research

Volumn 64, Issue 3, 2004, Pages 507-515

  Porter, Karen E ^a   Turner, Neil A ^a   O'Regan, David J ^b   Ball, Stephen G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Human atrial myofibroblast; MMP 9; Tumor necrosis factor

Indexed keywords

GELATINASE B; MATRIGEL; MESSENGER RNA; NEUTRALIZING ANTIBODY; RECEPTOR SUBTYPE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; CELL COUNT; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HEART ATRIUM; HEART ATRIUM APPENDAGE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; ZYMOGRAPHY;

CELL COUNT; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEART ATRIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATRIX METALLOPROTEINASE 9; MYOBLASTS, CARDIAC; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8644255077     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.07.020     Document Type: Article

References (49)

1. J.N. Cohn, R. Ferrari, and N. Sharpe Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling J. Am. Coll. Cardiol. 35 2000 569 582
2. A. Khan, G.W. Moe, N. Nili, E. Rezaei, M. Eskandarian, and J. Butany The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure J. Am. Coll. Cardiol. 43 2004 68 76
3. V.L. Thijssen, J. Ausma, G.S. Liu, M.A. Allessie, G.J. van Eys, and M. Borgers Structural changes of atrial myocardium during chronic atrial fibrillation Cardiovasc. Pathol. 9 2000 17 28
4. G. Serini, and G. Gabbiani Mechanisms of myofibroblast activity and phenotypic modulation Exp. Cell Res. 250 1999 273 283
5. M. Eghbali Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation Basic Res. Cardiol. 87 1992 183 189
6. K.T. Weber, C.G. Brilla, and J.S. Janicki Myocardial fibrosis: functional significance and regulatory factors Cardiovasc. Res. 27 1993 341 348
7. F.G. Spinale, H. Gunasinghe, P.D. Sprunger, J.M. Baskin, and W.C. Bradham Extracellular degradative pathways in myocardial remodeling and progression to heart failure J. Card. Fail. 8 2002 S332 S338
8. J.T. Peterson, H. Hallak, L. Johnson, H. Li, P.M. O'Brien, and D.R. Sliskovic Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure Circulation 103 2001 2303 2309
9. L.E. Rohde, A. Ducharme, L.H. Arroyo, M. Aikawa, G.H. Sukhova, and A. Lopez-Anaya Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice Circulation 99 1999 3063 3070
10. A. Ducharme, S. Frantz, M. Aikawa, E. Rabkin, M. Lindsey, and L.E. Rohde Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction J. Clin. Invest. 106 2000 55 62
11. E.M. Wilson, H.R. Gunasinghe, M.L. Coker, P. Sprunger, D. Lee-Jackson, and B. Bozkurt Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure J. Card. Fail. 8 2002 390 398
12. Y.Y. Li, A.M. Feldman, Y. Sun, and C.F. McTiernan Differential expression of tissue inhibitors of metalloproteinases in the failing human heart Circulation 98 1998 1728 1734
13. Y. Nakano, S. Niida, K. Dote, S. Takenaka, H. Hirao, and F. Miura Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation J. Am. Coll. Cardiol. 43 2004 818 825
14. J. Xu, G. Cui, F. Esmailian, M. Plunkett, D. Marelli, and A. Ardehali Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation Circulation 109 2004 363 368
15. G. Torre-Amione, S. Kapadia, J. Lee, R.D. Bies, R. Lebovitz, and D.L. Mann Expression and functional significance of tumor necrosis factor receptors in human myocardium Circulation 92 1995 1487 1493
16. A. Deswal, N.J. Petersen, A.M. Feldman, J.B. Young, B.G. White, and D.L. Mann Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST) Circulation 103 2001 2055 2059
17. G. Torre-Amione, S. Kapadia, C. Benedict, H. Oral, J.B. Young, and D.L. Mann Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD) J. Am. Coll. Cardiol. 27 1996 1201 1206
18. B. Bozkurt, S.B. Kribbs, F.J. Clubb Jr., L.H. Michael, V.V. Didenko, and P.J. Hornsby Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats Circulation 97 1998 1382 1391
19. D. Bryant, L. Becker, J. Richardson, J. Shelton, F. Franco, and R. Peshock Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha Circulation 97 1998 1375 1381
20. J.B. Klein, G.W. Wang, Z. Zhou, A. Buridi, and Y.J. Kang Inhibition of tumor necrosis factor-alpha-dependent cardiomyocyte apoptosis by metallothionein Cardiovasc. Toxicol. 2 2002 209 218
21. T. Yokoyama, M. Nakano, J.L. Bednarczyk, B.W. McIntyre, M. Entman, and D.L. Mann Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes Circulation 95 1997 1247 1252
22. M. Jacobs, S. Staufenberger, U. Gergs, K. Meuter, K. Brandstatter, and M. Haffner Tumor necrosis factor-α at acute myocardial infarction in rats and effects on cardiac fibroblasts J. Mol. Cell. Cardiol. 31 1999 1949 1959
23. Y.Y. Li, Y.Q. Feng, T. Kadokami, C.F. McTiernan, R. Draviam, and S.C Watkins Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy Proc. Natl. Acad. Sci. U. S. A. 97 2000 12746 12751
24. N. Sivasubramanian, M.L. Coker, K.M. Kurrelmeyer, W.R. MacLellan, F.J. DeMayo, and F.G. Spinale Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor Circulation 104 2001 826 831
25. A. Cho, J. Graves, and M.A. Reidy Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells Arterioscler. Thromb. Vasc. Biol. 20 2000 2527 2532
26. E. Genersch, K. Hayess, Y. Neuenfeld, and H. Haller Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways J. Cell Sci. 113 Pt 23 2000 4319 4330
27. S.K. Moon, B.Y. Cha, and C.H. Kim ERK1/2 mediates TNF-a-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kB and AP-1: involvement of the ras dependent pathway J. Cell Physiol. 198 2004 417 427
28. S.A. Doggrell Statins in the 21st century: end of the simple story? Expert Opin. Investig. Drugs 10 2001 1755 1766
29. J. Bauersachs, P. Galuppo, D. Fraccarollo, M. Christ, and G. Ertl Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction Circulation 104 2001 982 985
30. S. Hayashidani, H. Tsutsui, T. Shiomi, N. Suematsu, S. Kinugawa, and T. Ide Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 105 2002 868 873
31. R. Patel, S.F. Nagueh, N. Tsybouleva, M. Abdellatif, S. Lutucuta, and H.A. Kopelen Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy Circulation 104 2001 317 324
32. J. Kjekshus, T.R. Pedersen, A.G. Olsson, O. Faergeman, and K. Pyorala The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease J. Card. Fail. 3 1997 249 254
33. S.F. Su, C.L. Hsiao, C.W. Chu, B.C. Lee, and T.M. Lee Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension Am. J. Cardiol. 86 2000 514 518
34. Y. Young-Xu, S. Jabbour, R. Goldberg, C.M. Blatt, T. Graboys, and B. Bilchik Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease Am. J. Cardiol. 92 2003 1379 1383
35. K. Node, M. Fujita, M. Kitakaze, M. Hori, and J.K. Liao Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 108 2003 839 843
36. T.B. Horwich, W.R. MacLellan, and G.C. Fonarow Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure J. Am. Coll. Cardiol. 43 2004 642 648
37. N.A. Turner, K.E. Porter, W.H. Smith, H.L. White, S.G. Ball, and A.J. Balmforth Chronic β2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism Cardiovasc. Res. 57 2003 784 792
38. K.E. Porter, N.A. Turner, D.J. O'Regan, A.J. Balmforth, and S.G. Ball Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA Cardiovasc. Res. 61 2004 745 755
39. N.A. Turner, S.G. Ball, and A.J. Balmforth The mechanism of angiotensin II-induced extracellular signal-regulated kinase-1/2 activation is independent of angiotensin AT1A receptor internalisation Cell. Signal. 13 2001 269 277
40. K.E. Porter, J. Naik, N.A. Turner, T. Dickinson, M.M. Thompson, and N.J. London Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration J. Vasc. Surg. 36 2002 150 157
41. O.J. Jupp, S.M. McFarlane, H.M. Anderson, A.F. Littlejohn, A.A.A. Mohamed, and R.H. MacKay Type II tumour necrosis factor-α receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways Biochem. J. 359 2001 525 535
42. Y. Higuchi, C.F. McTiernan, C.B. Frye, B.S. McGowan, T.O. Chan, and A.M. Feldman Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-α-induced cardiomyopathy Circulation 109 2004 1892 1897
43. J. Hellkvist, G. Tufveson, B. Gerdin, and C. Johnsson Characterization of fibroblasts from rejecting tissue: the hyaluronan production is increased Transplantation 74 2002 1672 1677
44. D.A. Siwik, D.L. Chang, and W.S. Colucci Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro Circ. Res. 86 2000 1259 1265
45. W.R. Wong, S. Kossodo, and I.E. Kochevar Influence of cytokines on matrix metalloproteinases produced by fibroblasts cultured in monolayer and collagen gels J. Formos. Med. Assoc. 100 2001 377 382
46. C. Denoyelle, P. Albanese, G. Uzan, L. Hong, J.P. Vannier, and J. Soria Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells Cell. Signal. 15 2003 327 338
47. I.K. Wang, S.Y. Lin-Shiau, and J.K. Lin Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation Oncology 59 2000 245 254
48. G. Valen, G. Paulsson, A.M. Bennet, G.K. Hansson, and J. Vaage Gene expression of inflammatory mediators in different chambers of the human heart Ann. Thorac. Surg. 70 2000 562 567
49. P.A. Henriksen, and D.E. Newby Therapeutic inhibition of tumour necrosis factor a in patients with heart failure: cooling an inflamed heart Heart 89 2003 14 18